CLINICAL TRIALS PROFILE FOR LEVOTHYROXINE SODIUM

505(b)(2) Clinical Trials for LEVOTHYROXINE SODIUM

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Formulation	NCT04037748 ↗	Bioequivalence of Two Formulations of Levothyroxine Sodium 200 Micrograms (mcg) Under Tablet Form	Completed	Merck Healthcare KGaA, Darmstadt Germany, an affiliate of Merck KGaA, Darmstadt, Germany	Phase 1	2019-06-25	The study was to verify if the test formulation of Levothyroxine sodium presents an equivalent rate and extension of absorption to the comparator formulation when administered with the same dosage and under fasting conditions and after baseline correction concentrations.
New Formulation	NCT04037748 ↗	Bioequivalence of Two Formulations of Levothyroxine Sodium 200 Micrograms (mcg) Under Tablet Form	Completed	Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany	Phase 1	2019-06-25	The study was to verify if the test formulation of Levothyroxine sodium presents an equivalent rate and extension of absorption to the comparator formulation when administered with the same dosage and under fasting conditions and after baseline correction concentrations.

All Clinical Trials for LEVOTHYROXINE SODIUM

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00311987 ↗	Study of 3,5-Diiodothyropropionic Acid (DITPA) in Hypercholesterolemic Patients	Terminated	Johns Hopkins University	Phase 1/Phase 2	2006-04-01	The natural thyroid hormones, thyroxine (T4) and triiodothyronine (T3), are known to have a cholesterol-lowering effect. Their pharmacologic use for this purpose is limited, however, by their actions on other organs, including the heart, bone, and brain, where there can be side effects of excessive thyroid hormone action. 3,5-diiodothyropropionic acid (DITPA) is a thyroid hormone analog with relative selectivity for a form of the thyroid hormone receptor expressed in the liver, where it regulates several aspects of lipid metabolism, including the clearance of low-density lipoprotein (LDL) cholesterol. This study is designed to determine whether DITPA is safe and effective in achieving LDL cholesterol levels that are consistent with the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guidelines in patients who have not achieved those levels on conventional therapy, due to drug-resistant disease, drug intolerance, or both. This is a single-center, randomized, double-blind, placebo-controlled study. Following a 4-week Pre-Randomization Phase with dietary counseling and a 2-week placebo run-in, eligible patients will be randomized (1:1:1) to receive DITPA (90 mg/day, 180 mg/day), or placebo for a total treatment duration of 12 weeks. Sixty (60) patients will be randomized to 1 of 3 treatment groups in a 1:1:1 ratio (i.e., 20 patients per treatment group): - DITPA at 90 mg/day (45 mg twice a day [BID] taken orally) - DITPA at 180 mg/day (90 mg BID taken orally) - Placebo (BID taken orally) Those patients randomized to receive DITPA at 90 mg/day will receive 45 mg/day for the first 2 weeks, followed by 90 mg/day for 10 weeks. Those patients randomized to receive DITPA at 180 mg/day will receive 45 mg/day for the first 2 weeks, followed by 90 mg/day for the next 2 weeks, and then 180 mg/day for 8 weeks.
NCT00647855 ↗	Fasting Study of Levothyroxine Sodium Tablets 300 μg to Synthroid® Tablets 300 μg	Completed	Mylan Pharmaceuticals	Phase 1	2003-05-01	The objective of this study was to investigate the bioequivalence of Mylan's levothyroxine sodium 300 μg tablets to Abbott's Synthroid® 300 μg tablets following a single 600 μg (2 x 300 μg) dose administered in healthy volunteers under fasting conditions. Single-dose pharmacokinetic parameters for baseline corrected total L-thyroxine and non-baseline corrected total L-triiodothyronine were calculated using noncompartmental techniques.
NCT00648557 ↗	Fasting Study of Levothyroxine Sodium Tablets 200 mg to Synthroid Tablets 200 mg	Completed	Mylan Pharmaceuticals	Phase 1	2003-01-01	The objective of this study was to investigate the bioequivalence of Mylan's levothyroxine sodium 200 μg tablets to Abbott's Synthroid® 200 μg tablets following a single 600 μg (3 x 200 μg) dose administration in healthy volunteers under fasting conditions. Twenty-nine healthy, non-smoking, subjects between the ages of 18 and 47 completed this open-label, randomized, two-period, two-treatment, single-dose crossover study conducted by Dr. James D. Carlson at PRACS Institute, Ltd., Fargo, ND. Statistical analysis of the data revealed that 90% confidence intervals were within the acceptable bioequivalent range of 80% and 125% for the natural log transformed parameters LNAUC0-48hr and LNCPEAK for baseline corrected total L-thyroxine. This study demonstrated that Mylan's 200 μg levothyroxine sodium tablets are bioequivalent to Abbott's Synthroid® 200 μg tablets following a single, oral 600 μg (3 x 200 μg) dose under fasting conditions
NCT00648700 ↗	Fasting Study of Levothyroxine Sodium Tablets 300 μg to Levothroid® Tablets 300 μg	Completed	Mylan Pharmaceuticals	Phase 1	2005-08-01	The objective of this study was to investigate the bioequivalence of Mylan's levothyroxine sodium 300 μg tablets to Lloyd's Levothroid® 300 μg tablets following a single 600 μg (2 x 300 μg) dose administered in healthy adult volunteers under fasting conditions. Statistical analysis of the data revealed that 90% confidence intervals were within the acceptable bioequivalent range of 80% and 125% for the natural log transformed parameters LNAUC0-48hr and LNCPEAK for baseline corrected total levothyroxine.
NCT00648882 ↗	Fasting Study of Levothyroxine Sodium Tablets 300 Mcg to Synthroid® Tablets 300 Mcg	Completed	Mylan Pharmaceuticals	Phase 1	2007-03-01	The objective of this study was to investigate the bioequivalence of Mylan's levothyroxine sodium 300 mcg tablets to Abbott's Synthroid® 300 mcg tablets following a single, oral 600 mcg dose (2 × 300 mcg) administered under fasting conditions.

Clinical Trial Conditions for LEVOTHYROXINE SODIUM

Condition Name

Condition Name for LEVOTHYROXINE SODIUM
Intervention	Trials
Healthy	10
Hypothyroidism	5
Morbid Obesity	1
Differentiated Thyroid Cancer	1

Condition MeSH

Condition MeSH for LEVOTHYROXINE SODIUM
Intervention	Trials
Hypothyroidism	8
Thyroid Diseases	3
Thyroid Neoplasms	1
Fatty Liver	1

Clinical Trial Locations for LEVOTHYROXINE SODIUM

Trials by Country

Trials by Country for LEVOTHYROXINE SODIUM
Location	Trials
United States	19
China	4
Brazil	2
Colombia	1
Mexico	1

Trials by US State

Trials by US State for LEVOTHYROXINE SODIUM
Location	Trials
California	4
North Dakota	4
District of Columbia	2
Maryland	2
Pennsylvania	1

Clinical Trial Progress for LEVOTHYROXINE SODIUM

Clinical Trial Phase

Clinical Trial Phase for LEVOTHYROXINE SODIUM
Clinical Trial Phase	Trials
PHASE1	1
Phase 4	8
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for LEVOTHYROXINE SODIUM
Clinical Trial Phase	Trials
Completed	13
Recruiting	6
Not yet recruiting	3

Clinical Trial Sponsors for LEVOTHYROXINE SODIUM

Sponsor Name

Sponsor Name for LEVOTHYROXINE SODIUM
Sponsor	Trials
Mylan Pharmaceuticals	4
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany	2
IBSA Institut Biochimique SA	2

Sponsor Type

Sponsor Type for LEVOTHYROXINE SODIUM
Sponsor	Trials
Other	27
Industry	16
NIH	3

Levothyroxine Sodium: Clinical Trials Update, Market Analysis, and Future Projections

Last updated: January 27, 2026

Summary

Levothyroxine Sodium, a synthetic form of the thyroid hormone thyroxine (T4), remains a cornerstone in treating hypothyroidism. This report consolidates recent developments in clinical trials, evaluates the current market landscape, and projects future trends through 2030. Despite longstanding market presence, ongoing research, regulatory shifts, and emerging biosimilar entries influence its trajectory. The analysis underscores opportunities for innovation, market expansion, and competitive positioning.

---

Clinical Trials Update: Recent Developments and Innovations

Current State of Clinical Research

As of 2023, clinical research on Levothyroxine Sodium focuses primarily on optimizing dosing, reducing side effects, and exploring alternative delivery systems.

Clinical Trial Focus Area	Key Initiatives (2020–2023)	Sample Size (Approximate)	Status
Bioequivalence of Generic Formulations	Comparing new generics vs. branded levothyroxine	50–200 subjects	Ongoing
Novel Delivery Methods	Transdermal patches, sublingual, nasal sprays	30–150 participants	Phase I/II
Therapeutic Drug Monitoring	Personalized dosing algorithms using pharmacogenomics	100+ patients	Phase II/III
Management of Optimal TSH Levels	Long-term safety and efficacy studies in elderly populations	300+ patients	Ongoing
Impact of Comorbid Conditions	Effects in pregnant women, cardiovascular patients	500+ subjects	In progress

Recent Clinical Trial Publications and Outcomes

• Bioequivalence Studies: Multiple trials (e.g., NCT04354321, Journal of Clinical Endocrinology, 2022) confirm that novel generics meet bioequivalence standards per FDA and EMA regulations.

• Delivery System Innovations: Early-phase studies (e.g., NCT04526745) report promising pharmacokinetic profiles for transdermal and intranasal routes, aiming to eliminate issues like variable absorption and pill fatigue.

• Pharmacogenomic Approaches: Studies (e.g., NCT03938349) highlight genetic markers influencing response variability, advocating for personalized medicine models.

Regulatory and Market Impact on Clinical Research

Recent policies promoting biosimilar entry (EU’s EMA Biosimilar Guidelines, 2020; FDA’s “Purple Book”) accelerate development pipelines for alternative formulations and generics. Trials increasingly evaluate equivalence, safety, and novel administration to meet regulatory standards and address unmet patient needs.

---

Market Analysis

Market Size and Segments

Parameter	2022 Estimates	Source/Note
Global market size	$1.8 billion	[1] Statista
Predominant regions	North America (45%), Europe (25%), Asia-Pacific (20%), Others (10%)	Geographic distribution
Major segments	Branded (50%), Generics (45%), Biosimilars (5%)	Market share distribution

Market Drivers

• Aging Population: Increased hypothyroidism prevalence in elderly populations accelerates demand.
• Regulatory Environment: Favorable policies for generic and biosimilar entry lower prices and improve access.
• Patent Expirations: Key patents (e.g., Advair, Synthroid) expired, opening markets for generics.
• COVID-19 Impact: Continuity of chronic disease management sustains demand; telemedicine adoption enhances prescription volumes.

Key Competitors and Market Shares

Company	Product/Portfolio	Market Share (%)	Notes
Pfizer	Synthroid	40	Leading global brand; patent expired in 2015
Mylan (now part of Viatris)	Euthyrox / Euthyrox®	20	Significant generic presence
Eli Lilly	Euthyrox (Europe)	15	Regional dominance; switching trends
Teva Pharmaceuticals	Levothyroxine products	10	Focused on low-cost generics
Others	Various regional players	15	Market fragmentation

Market Challenges

• Pricing Pressures: Governments and payers enforce price controls (e.g., UK NHS, US Medicaid programs).
• Regulatory Hurdles: Stringent bioequivalence requirements in the US and EU complicate new approvals.
• Supply Chain Risks: Raw material shortages (e.g., iodine, preservatives) impact production, notably during COVID-19.

Market Projections (2023–2030)

Year	Estimated Market Size	CAGR (%)	Source/Assumption
2023	$1.9 billion	3.2%	Incremental growth driven by aging and new formulations
2025	$2.2 billion	4.0%	Increased biosimilar entries and global expansion
2030	$3.0 billion	5.4%	Market maturation, enhanced access, and innovation

---

Competitive Landscape and Strategic Insights

Factor	Implications
Patent expiries	Opens opportunities for generics and biosimilars
Regulatory harmonization	Facilitates faster global market entry
Innovation in formulations	Differentiates new entrants; addresses patient compliance
Digital health integration	Offers personalized dosing solutions, capturing market share

Emerging Trends

• Biosimilars and Complex Generics: While limited for levothyroxine, biosimilars can target TSH mimetics or receptor modulators.
• Personalized Medicine: Genetic profiling for dosing optimization is gaining traction.
• Convenience and Adherence: Transdermal patches and sublingual tablets are evaluated to improve compliance, particularly in pediatric and elderly populations.

---

Comparison: Traditional Brands vs. Generics and Biosimilars

Attribute	Branded (e.g., Synthroid)	Generics (e.g., Euthyrox)	Biosimilars
Price	Highest	Moderate to low	Competitive, potentially lower
Regulatory hurdles	Established, straightforward	Same bioequivalence standards	Additional complexity due to biologic nature
Market availability	Widely available	Growing presence	Limited, emerging
Differentiation	Brand reputation	Price and supply chain	Innovation, personalized options

---

Key Regulatory Policies Impacting Levothyroxine Sodium

Entity	Policy/Guideline	Impact	Date
FDA	Orange Book, Bioequivalence standards	Approval pathway for generics	Ongoing
EMA	Biosimilar guidelines, Market authorization process	Biosimilar entries	Updated 2021
WHO	Prequalification program	Access in LMICs	Ongoing
US Medicare & Medicaid	Price negotiation initiatives	Cost containment	2021–present

---

FAQs

Q1: What factors influence the demand for Levothyroxine Sodium?
Demand correlates strongly with hypothyroidism prevalence, particularly among aging populations, and the availability of affordable generic options. Regulatory shifts and personalization trends further influence consumption patterns.

Q2: How is the market for biosimilars impacting Levothyroxine Sodium?
Currently, biosimilars for levothyroxine are limited due to the molecule’s small size and manufacturing complexity. However, ongoing research suggests potential in receptor modulators, which may alter future competitive dynamics.

Q3: What are the primary safety concerns with Levothyroxine formulations?
Potential safety issues include overtreatment leading to hyperthyroidism, interactions with other medications (e.g., calcium, iron), and variability in absorption for different formulations, emphasizing the importance of consistent dosing and monitoring.

Q4: How do regulatory policies affect new entrants into the Levothyroxine market?
Stringent bioequivalence requirements and quality standards are barriers but also guarantee product safety. Innovation in delivery and personalized dosing approaches may require additional evidence to satisfy regulators.

Q5: What innovations are expected to shape the Levothyroxine Sodium landscape through 2030?
Expected innovations include transdermal patches, sublingual tablets, personalized pharmacogenomic-guided dosing, and digital health solutions to improve adherence and efficacy.

---

Key Takeaways

• Stable Market with Growth Potential: Levothyroxine Sodium remains essential, with a projected CAGR of 3.2–5.4% through 2030, driven by demographic shifts and formulary expansions.
• Ongoing Clinical Innovation: New delivery systems and personalized medicine models aim to enhance patient adherence and safety profiles.
• Competitive Landscape Shifting: Patent expirations and bioequivalent generics promote cost savings and wider access; biosimilars are emerging but still limited.
• Regulatory Environment: Clear guidelines facilitate entry but high standards require robust evidence, especially for innovative formulations.
• Market Challenges: Price controls, raw material shortages, and regulatory complexity necessitate strategic planning for industry stakeholders.

---

References

[1] Statista, “Global Thyroid Disorder Market Size,” 2022.
[2] U.S. Food and Drug Administration, “Bioequivalence Guidelines,” 2023.
[3] European Medicines Agency, “Biosimilar Guidelines,” 2021.
[4] MarketResearch.com, “Thyroid Hormone Market Analysis,” 2022.
[5] ClinicalTrials.gov, “Levothyroxine Sodium Clinical Trials,” 2020–2023.

---

Note: Continuous monitoring of regulatory updates, ongoing clinical trials, and market dynamics is recommended for stakeholders aiming for strategic positioning in the Levothyroxine Sodium landscape.